Elizabeth Masson-Hurlburt
Corporate Officer/Principal bij CORMEDIX INC.
Vermogen: 192 483 $ op 31-03-2024
Profiel
Elizabeth Masson-Hurlburt is currently the Chief Clinical Strategy & Operations Officer at CorMedix, Inc. Prior to her current position, she worked as the Vice President-Clinical Operations at Gemphire Therapeutics, Inc. from 2016 to 2018.
Ms. Masson-Hurlburt completed her undergraduate degree at Bay Path College.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CORMEDIX INC.
0.08% | 12-01-2024 | 45 397 ( 0.08% ) | 192 483 $ | 31-03-2024 |
Actieve functies van Elizabeth Masson-Hurlburt
| Bedrijven | Functie | Begin |
|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | - |
Eerdere bekende functies van Elizabeth Masson-Hurlburt
| Bedrijven | Functie | Einde |
|---|---|---|
| NEUROBO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01-03-2018 |
Opleiding van Elizabeth Masson-Hurlburt
| Bay Path College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CORMEDIX INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Gemphire Therapeutics, Inc.
 Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI. | Health Technology |
